Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a phone app learn to count carbs and dose insulin?

NCT ID NCT07884526

Disease control Sponsor: Tan Tock Seng Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 20, 2026 · Last updated Oct 21, 2026 · Updated 1 time

Summary

Researchers are testing a mobile app called AI-CARE that uses artificial intelligence to estimate carbohydrates from photos of meals and suggest mealtime insulin doses. The study enrolls adults with type 1 or type 2 diabetes who take multiple daily insulin injections and wear a continuous glucose monitor. Participants are randomly assigned to use the app or receive usual care for 12 weeks. The trial measures whether the app is practical to use, whether it is safe, and how it affects blood sugar and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an AI-powered mobile app that estimates carbohydrates from meal photos and suggests insulin doses
What this could lead to
If it works, the app could help people with diabetes adjust mealtime insulin more easily and keep blood sugar in a safer range.
What could go wrong
This is a small, short pilot study, so it can only show whether the app is practical and safe enough to test further. The AI may misjudge carb amounts, and insulin dosing errors can cause dangerous low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * have type 1 or type 2 diabetes and are receiving multiple daily insulin injections * have an HbA1c ≥7% * are willing to wear a CGM sensor for 12 weeks * are able to read and understand English. Exclusion Criteria: * are pregnant * have experienced severe hypoglycaemia or diabetic ketoacidosis within the preceding three months * have hypoglycaemia unawareness * insulin-to-carbohydrate ratio is below 8 * have significant cognitive impairment that may interfere with the use of the application.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tan Tock Seng Hospital

    Singapore, Singapore, 308433, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.